BOVIVAC S

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

SALMONELLA DUBLIN STRAIN S342/70 FORMALIN INACTIVATED, SALMONELLA TYPHIMURIUM STRAIN S341/70 FORMALIN INACTIVATED

Available from:

Intervet Ireland Limited

ATC code:

QI02AB

INN (International Name):

SALMONELLA DUBLIN STRAIN S342/70 FORMALIN INACTIVATED, SALMONELLA TYPHIMURIUM STRAIN S341/70 FORMALIN INACTIVATED

Dosage:

Unknown

Pharmaceutical form:

Suspension for Injection

Prescription type:

POM(E)

Therapeutic group:

Bovine

Therapeutic area:

Inactivated bacterial vaccines (including Mycoplasma, Toxoid and Chlamydia vaccines)

Therapeutic indications:

Immunological - Inactivated vaccine

Authorization status:

Authorised

Authorization date:

2001-09-05

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovivac S
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
PER ML:
ACTIVE SUBSTANCES:
Formalin killed cells of _Salmonella dublin _strain S342/70
1 x 10
9
cells
Formalin killed cells of _Salmonella typhimurium _strain S341/70 1 x 10
9
cells
ADJUVANT:
Aluminium hydroxide gel
200 mg
EXCIPIENTS:
The vaccine contains thiomersal as a preservative
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Suspension for injection
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of cattle in order to induce serological and colostral antibody production against
_Salmonella dublin _and _Salmonella typhimurium _and in the face of an outbreak to reduce _Salmonella typhimurium_
infections when used under field conditions as part of an overall herd management programme. Bovivac S may also
contribute to reducing _S. typhimurium _contamination of the environment.
Specific experimental data to quantify the duration of immunity or the degree of protection from colostral antibodies
has not been generated.
Significant levels of immunity cannot be expected until two weeks after the second dose of the primary vaccination
course.
4.3 CONTRAINDICATIONS
None.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 30/03/2012_
_CRN 7012227_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
All stock showing overt clinical signs of salmonellosis at the time of the initial vaccination programme should receive
appropriate treatment and be fully vaccinated once they have recovered. Any unvaccina